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Low-dose chest tomography (LDCT) screening in high-risk patients (individuals age 55-74 with 
a 30-pack-year smoking history in a current smoker, or similar smoking history in a former 
smoker who quit within the past 15 years) has proven to reduce both lung cancer and all-cause 
mortality by 20% and 7%, respectively (Aberle et al., 2011).  Despite endorsement by medical 
and nursing organizations and payers, as well as the strong evidence in support of LDCT 
screening (Aberle et al., 2011), lung cancer screening rates nationwide remain low at 1.9% 
(Pham et al., 2018).   The goal of this Doctor of Nursing (DNP) quality improvement project was 
to improve lung cancer screening in eligible Medicaid recipients in a rural primary care practice. 
The process to improve screening included primary care provider (PCP) education and 
incorporating a lung cancer risk assessment tool into the practice EHR to assist the PCP to 
appropriately identify eligible patients for LDCT screening and to increase appropriate LDCT 
screening referrals. The patient sample included 34 participants who met the USPSTF lung 
cancer screening eligibility criteria (ages 55-80, documented pack-year smoking history and 
asymptomatic) from the total Medicaid practice population (N=184) seen during the study 
period.  Data was gathered for three months before and after implementation of the lung cancer 
risk assessment tool. While our project found no significant improvement in the primary 
outcome of LDCT screening referral rates in the patient sample, it does provide data on current 
LDCT referral rates in a high-risk North Carolina Medicaid population.  Future practice 
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improvement projects should include educational interventions to increase PCP knowledge of 
lung cancer screening and process improvements in gathering accurate USPSTF lung cancer 
screening patient eligibility criteria of pack-years smoking history documentation in the EHR. 
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   CHAPTER 1: INTRODUCTION 
 
Rates of cigarette smoking in North Carolina continue to exceed the national average of 
(17.9% vs. 16.4%) placing many North Carolinians at risk for developing smoking related lung 
cancer (National Institutes of Health, 2018).  North Carolina Medicaid enrollees, aged 16-64, 
report much higher smoking rates at 43.3% (State Center for Health Statistics, North Carolina 
Department of Public Health, 2016).  Minorities and those who are socioeconomically 
disadvantaged (measured by wealth, income distribution, poverty rate, unemployment rate, 
education, occupation and housing quality) have not only higher smoking prevalence and higher 
lung cancer incidence, but also higher mortality rates (Singh, Williams, Siahpush, & Mulhollen, 
2011). Those with a low socioeconomic status smoke cigarettes more heavily with a duration 
nearly twice as many years than those with a family income of three times the poverty rate 
(Siahpush, Singh, Jones, & Timsina, 2009).   Socioeconomically disadvantaged patients are more 
likely to be diagnosed with later-stage cancer and less likely to receive any treatment, surgery, 
and chemotherapy for lung cancer (Woods, Rachet, & Coleman, 2006).  
With 75% of lung cancers in an advanced stage at diagnosis, there is only a 4% five-year 
survival rate (Siegel, Miller, & Jemal, 2017).  Lung cancers can be detected at earlier phases 
through low-dose computed tomography (LDCT) screening of high-risk patients, a service that is 
described by some advocates as a "game changer" in the battle against lung cancer (Carter-Harris 
& Gould, 2017).  LDCT screening in high-risk patients (individuals age 55-74 with a 30-pack-
per year smoking history in a current smoker, or similar smoking history with quitting within the 
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past 15 years) has proven to reduce both lung cancer and all-cause mortality by 20% and 7%, 
respectively (Aberle et al., 2011).  Despite strong evidence in support of LDCT screening with 
proven reductions in lung cancer associated morbidity and mortality (Aberle et al., 2011), and 
the resulting endorsement by medical and nursing organizations and payers, screening rates 
nationwide remain low at 1.9% (Pham, Bhandari, Oechsli, Pinkston & Kloecker, 2018).  
Problem Statement 
 
North Carolina Medicaid enrollees (adults aged 18-64 years, non-institutionalized) report 
current smoking rates of 43.3%, placing these enrollees at high risk for lung cancer while also 
being at high risk for healthcare disparities due to their socioeconomic status (State Center for 
Health Statistics, North Carolina Department of Public Health, 2016).  However, LDCT 
screening guidelines have not been widely implemented into national evidence-based clinical 
practice as evidenced by a low national lung cancer screening rate of only 1.9% (Pham et al., 
2018).  Many patient, provider and system level barriers have been suggested as reasons for low 
screening rates (Carter-Harris & Gould, 2017).  There is currently no data published on the 
estimated or actual numbers of lung cancer screenings in the North Carolina Medicaid 
population.  If the North Carolina Medicaid population does not have access to screening, this 
gap in care may be contributing to healthcare disparities and poor outcomes. 
Purpose 
 
The purpose of this Doctor of Nursing Practice (DNP) practice improvement project is to 
improve the primary care provider’s (PCP’s) identification of North Carolina Medicaid enrollees 
at high risk for lung cancer and appropriately refer for LDCT screening in an effort to detect 
early-stage lung cancer and decrease lung cancer mortality in a rural community practice.   
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Background and Significance 
 
Lung cancer statistics.  Lung cancer is the third most common cancer and the leading 
cause of cancer deaths in the United States in both men and women, accounting for one quarter 
of cancer deaths, and kills more people than breast cancer, prostate cancer, and colon 
cancer combined. (American Cancer Society, 2019a).  The burden of lung cancer in incidence 
and mortality rates in North Carolina is, on average, higher than that of the United States. Lung 
cancer was the leading cause of cancer mortality in North Carolina from 2012- 2016 with 27,600 
deaths (North Carolina Department of Health and Human Services, 2018). It is estimated that 
8,010 North Carolinians will be diagnosed with lung cancer and 5,370 people will die from lung 
cancer in 2019 (American Cancer Society, 2019b)   
Despite improvements in patient survival over the last several decades for other cancer 
types, including breast and prostate cancer, there have been comparatively marginal 
improvements in lung cancer survival. The lack of significant improvement in lung cancer 
survival is largely attributed to the advanced stage at time of diagnosis offering limited treatment 
options. The national five-year survival rate for lung cancer is 55% when the disease is detected 
early and still localized within the lungs. However, only 16% of lung cancer cases are diagnosed 
at an early stage. Unfortunately, lung cancer is primarily detected when the patient has become 
symptomatic and the cancer has spread to other organs with a five-year survival rate of only 4% 
(American Lung Association, 2016). 
Perhaps the easiest way to improve lung cancer survival is early detection, as suggested 
by Carbone & colleagues (1970).  The earlier lung cancer is detected, the better chance a person 
has of surviving years after time of diagnosis.  The extent of lung cancer in the body, or stage, 
guides treatment options and influences the length of survival following diagnosis.  Nationally, 
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Stage I lung cancer is localized to a primary site (the lung) and represents only 16% of newly 
diagnosed patients.  According to the SEER database, 60% of patients with non-small cell lung 
cancer and 29% of patients with small cell lung cancer at a localized (traditionally Stage 1) are 
alive at five years after diagnosis (American Cancer Society, 2019c).  Twenty-two percent of 
American lung cancer patients are diagnosed with regional disease, Stages II and III, where the 
cancer has spread outside of the lung to the lymph nodes, tissues or other organs (National 
Cancer Institute, 2018).  These patients have a 29.7% five-year survival rate.  Nationally, 
approximately 80% of lung cancers are of late stage (Stage IV) at time of diagnosis, conferring 
poor treatment options and poorer outcomes (SEER, 2018).  Fifty-seven percent of patients are 
diagnosed with distant lung cancer, Stage IV, where the cancer has metastasized and most 
difficult to treat resulting in five-year survival rates of less than 5% (SEER, 2018).  In contrast, 
North Carolina data on stage of lung cancer at diagnosis is: 18.9% are localized; 24.6% are 
regional; and 50.1% are distant (North Carolina State Center for Health Statistics, 2017).  
Currently, stage-specific five-year survival data is not available for North Carolina (American 
Lung Association, 2019). 
Smoking.  It is estimated that 85-90% of lung cancers are attributable to smoking 
(Centers for Disease Control and Prevention, 2017a).  Despite the declining prevalence of 
current cigarette smoking among U.S. adults from 20.9% in 2005 to 14.0% in 2017 (Centers for 
Disease Control and Prevention, 2017b), approximately 42.1 million American adults still smoke 
cigarettes (Jamal et al., 2014). In 2014, approximately 40% of adult Americans were current or 
former smokers (Jamal et al., 2014).  Clearly, smoking related lung cancer continues to be a 
major public health problem in the United States and will continue for decades to come. 
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Mirroring national trends, the smoking rates have decreased overall in North Carolina 
from 21.8 in 2011 to 17.9 in 2016, yet much more work needs to be done (Centers for Disease 
Control and Prevention, 2017c).  Rates of current cigarette smoking in North Carolina continue 
to exceed the national average placing many North Carolinians at risk for developing lung cancer 
(National Institutes of Health, 2018). North Carolina Medicaid smoking rates are higher than for 
other North Carolinians placing these enrollees at high risk for lung cancer.  One study showed 
that 43.3% of non-institutionalized adults aged 18-64 years enrolled in North Carolina Medicaid 
reported current smoking compared to 32.2% with no health insurance reported smoking and 
16.2% with other health insurance (State Center for Health Statistics, North Carolina Department 
of Public Health, 2016).  
Healthcare disparities.  Nationally, adult cigarette smoking has declined from 20.9% in 
2005 to 14% in 2017 (Centers for Disease Control and Prevention, 2017a).  Smoking rates in 
North Carolina adults also decreased from 20.9% to 17.2% from 2012 to 2017.  However, while 
adult cigarette smoking rates has decreased overall nationally, there are certain populations 
where smoking remains high. Those at higher risk include: certain races and ethnicities; young 
adults; low socioeconomic status; males; living in the South and Midwest; low education; 
disabled; and lesbian, gay or bisexual individuals (Centers for Disease Control and Prevention, 
2017a).  While lung cancer is one of the few cancers in which African Americans fare slightly 
better than white patients in incidence and mortality rates on a statewide level, 53% of cases in 
African Americans are diagnosed at a distant stage compared to 50% in American Indians, 49% 
in Whites, and 48% in Hispanics (North Carolina Cancer Prevention and Control Branch/N.C. 
Comprehensive Cancer Control Program, 2017).  The lung cancer incidence rate for American 
Indians has risen since 1996 more than any other measurable racial or ethnic group in the state 
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(North Carolina Cancer Prevention and Control Branch/N.C. Comprehensive Cancer Control 
Program, 2017).  
While lung cancer mainly occurs in older people, approximately 30% are less than 65 
years of age at time of lung cancer diagnosis (North Carolina Cancer Prevention and Control 
Branch/N.C. Comprehensive Cancer Control Program, 2017).  Of those Americans diagnosed 
with lung cancer each year, it is estimated that approximately 8% of those are aged 45-54 years 
old and 22% of those are aged 55-64 years old (North Carolina Cancer Prevention and Control 
Branch/N.C. Comprehensive Cancer Control Program, 2017).  However, most people diagnosed 
with lung cancer are 65 or older, with 70 years being the national median age at time of 
diagnosis.  While those older than 65 years will qualify for Medicare for insurance coverage, 
those younger than 65 years may not have health insurance. 
Recognition of social determinants of health, disparities, inequities and care gaps are 
important when evaluating smoking related lung cancer in North Carolina. Poorer overall health, 
a higher prevalence of comorbid conditions, and greater life stress may also be a function of the 
challenges Medicaid enrollees face navigating the health care system, including the financial and 
logistical barriers they encounter when accessing care and historic distrust of a system that’s not 
designed around their needs (Forrest, Adams, Wareham, Rubin, & White, 2013).  Medicaid 
beneficiaries are often in poorer health before their lung cancer diagnosis—making their 
treatment much more complex.  Medicaid or uninsured patients have higher co-morbidity rates 
with more than a third being obese, approximately 20% being treated for depression, 20% with 
high blood pressure, and 15% having diabetes (Mendes, 2013). 
Socioeconomically disadvantaged patients are less likely to have a usual source of 
primary care and may face more problems in gaining access to high-quality oncology providers. 
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There are fewer doctors in North Carolina, with just 139 PCPs per 100,000 people, compared to 
154 per 100,000 in the rest of the United States (America’s Health Rankings® 2016 Annual 
Report, 2017).  North Carolina invests fewer resources into public health funding ($56 per 
person) than the rest of the nation ($98 per person)—a difference of nearly $42 (America’s 
Health Rankings® 2016 Annual Report, 2017).  More than 72% patients diagnosed with lung 
cancer between 2010 and 2014 received their primary health insurance through at least one type 
of governmental program (North Carolina Cancer Prevention and Control Branch/N.C. 
Comprehensive Cancer Control Program, 2017). 
Outcome disparities among low-income populations demonstrate they are at higher risk 
for poorer treatment outcomes (North Carolina Department of Health and Human Services, 
2017). Patients with Medicaid or no insurance consistently have worse outcomes than other 
patients with lung cancer (Mendes, 2013).  These poorer outcomes include higher risks of death 
than privately insured patients, as well as African-Americans and Hispanics—groups that are 
disproportionately represented in Medicaid programs—have higher lung cancer incidence and 
higher lung cancer mortality rates when compared with non-Hispanic whites and those with 
higher socioeconomic status (Mendes, 2013).  
Early detection of lung cancer.  Millions of Americans continue to smoke justifying 
continued investment in widespread smoking cessation efforts. Even if successful, a former 
smoker still is at increased risk for developing lung or other smoking related cancers. Therefore, 
uncovering ways to improve lung cancer survival by finding lung cancer at earlier stages of 
disease is of great importance. Early detection in initial lung cancer screening trials evaluating 
the use of a variety of tools failed to impact survival outcomes (Oken et al., 2011).  Several 
randomized controlled trials (RCTs) comparing chest radiographs (CXR) with or without sputum 
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cytology conducted prior to the 1990’s failed to show a statistically significant reduction in lung 
cancer mortality (Wender et al, 2013). As a result, the American Cancer Society removed its 
initial endorsement for lung cancer screening with CXR for current and former smokers (Wender 
et al., 2013). However, research continued to evaluate alternative methods, such as LDCT, for 
early detection of lung cancer.  Many of these LDCT randomized clinical trials compared LDCT 
to CXR with or without sputum cytology with mixed results. 
In late 2013, the United States Preventative Services Task Force (USPSTF) issued a 
Grade B recommendation and endorsed annual LDCT screening in individuals at high risk for 
developing lung cancer based on the results of the National Lung Screening Trial (Moyer, 2014).  
High risk is defined as adults aged 55-80 years who have at least a 30 pack-year smoking history 
and currently smoke or have quit within the past 15 years (USPSTF, 2013).  Prior to the USPSTF 
recommendations and reimbursement of screenings in December 2013, screening rates using 
LDCT were very low at 3.3% (Jemal & Fedewa, 2017).  In 2015, rates had only increased to 
3.9% after the Affordable Care Act mandated coverage of LDCT screening for high-risk 
privately insured individuals. The Centers for Medicare and Medicaid Services (CMS) initiated 
coverage for LDCT in February 2015 for eligible persons with a written prescription and shared 
decision-making (SDM) documentation (Simmons, Gray, Schabath, Wilson & Quinn, 2017). 
Professional organizations such as the American Cancer Society (ACS) and American Society of 
Clinical Oncology (ASCO) also supported adoption of LDCT screening in high-risk populations.  
Medicaid coverage of lung cancer screening was deferred to the individual states. 
Two years after these recommendations and national support for lung cancer screening, 
rates remained low despite the evidence that screening reduces lung cancer mortality.  The lack 
of screening means that only 262,700 of the eligible 6.8 million high-risk Americans were 
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evaluated for lung cancer despite the potential to thwart thousands of deaths annually (Jemal & 
Fedewa, 2017).  In the first national estimate of LDCT screening following the USPSTF 
recommendation in 2015, over 50% of smokers meeting USPSTF criteria for LDCT screening 
were Medicaid or uninsured (Jemal & Fedewa, 2017).  While this study was not designed to 
evaluate reasons for low uptake of LDCT screening, the authors proposed that reasons may 
include gaps in smoking knowledge regarding LDCT, lack of access to care, and lack of 
physician’s knowledge about screening recommendations and reimbursement (Jemal & Fedewa, 
2017).   
A more recent publication showed that annual LDCT screening remains inadequate 
following USPSTF recommendations despite the time since implementation and potential to 
prevent thousands of lung cancer deaths each year (Pham et al., 2018).  This study showed that in 
2016, only 1.9% of 7.6 million eligible smokers were screened by LDCT for lung cancer.   While 
the aim of this study was to update the number of LDCTs performed in the United States, the 
author speculated that reasons may range from lack of physician knowledge and referral, to lack 
of patient interest in and knowledge of screening (Pham et al., 2018). 
An important link between the high-risk patient and the LDCT screening center is the 
PCP.  The PCP most often represents the initial point of coordination of preventative care in the 
United States and where most cancer screening occurs opportunistically instead of through a 
specific organized screening program.  The PCP is well-positioned to assist the patient with 
decision-making for lung cancer screening interventions.  A study by Klabunde et al. (2012) 
evaluated PCP lung cancer screening practices in the United States.  This suggested improved 
education around existing barriers to screening identified by the PCP (evidence of LDCT, 
guidelines, potential harms, and costs) could address gaps in PCP LDCT knowledge.   
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Review of Literature 
 
The potential improvements in lung cancer and all-cause mortality and earlier stage at 
diagnosis with LDCT screening of a high risk patient population necessitates a review of the 
literature to more fully evaluate the benefits of lung cancer screening with LDCT.  Searches were 
conducted in CINAHL, PubMed and Embase (Appendix A).  The combined search terms 
included: (1) lung cancer screen*; AND (2) LDCT OR low dose chest tomography; AND (3) 
nurs* OR nurse practitioner OR physician assistant OR primary care OR family OR physician.  
Limitations on search terms included: language (English); publication years (5 years or 2012-
2017) plus known landmark studies; and age (middle aged+: 45 + years, middle aged: 45-64 
years, aged: 65+ years; and 80 and over or very elderly: 80+ years).  The search terms were all 
combined to yield 22 results in PubMed, six in CINAHL, and 32 in Embase. The addition of the 
search term “practice change” yield no results in any of the databases.  Forty-three articles were 
reviewed.  Of these results, four RCTs of LDCT screening were selected for inclusion in the 
review of literature as they were the only studies reporting results of both the intervention 
(LDCT) and control (non-LDCT) groups (Appendix B). 
Results and Discussion 
 
Of the four RCTs included in the review, only the National Lung Screening Trial (NLST) 
compared annual LDCT to annual CXR (Aberle et al., 2011).  In the largest high quality LDCT 
screening trial to date, the U.S. based, multicentered NLST enrolled 53,454 participants.  
Eligible participants were between the ages of 55-74 and current or former smoker (quit <15 
years ago) with >30 pack year smoking history.  Participants received three annual scans.   
The three remaining trials compared screening with LDCT to annual clinical review or 
usual care.  Sample sizes varied among these trials, as did enrollment eligibility. In contrast to 
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the NLST, the DANTE trial (Infante et al., 2009) enrolled 2472 participants comparing LDCT to 
annual clinical review.  This Italian study of three hospitals from the same network evaluated 
asymptomatic men between the ages of 60-74 who were current or former smokers with >20 
pack-year smoking history.  The DLCST trial (Saghir et al., 2012) randomized 4104 men and 
women at a single site in Denmark.  Participants were between the ages of 50-70 and current and 
former smokers (<10 years and > 4 weeks since smoking cessation) with >20 pack-year smoking 
history.  The MILD trial (Pastorino et al., 2012) evaluated LDCT (annual versus biennial) 
compared to usual care.  This single institution trial conducted in Milan enrolled 4099 
participants.  Current and former smokers, at least 49 years of age with no upper age limit, with a 
>20 pack-year smoking history or quit <10 years ago were eligible for study participation. 
Lung cancer mortality.  Clinical trial findings on lung cancer associated mortality were 
described in three of the four RCTs (Aberle et al., 2011; Infante et al., 2009; Saghir et al., 2012).  
The NLST reported a 20% reduction in lung cancer mortality with LDCT (95% CI, 6.8-26.7; p = 
0.004).  The study authors reported a number needed to screen (NNS) with LDCT to prevent one 
lung cancer death of 320 (among those undergoing ≥1 screens).  This is compared to screening 
900-1900 all-comers requiring screening mammograms to prevent one death from breast cancer, 
and screening 500 individuals with colonoscopy to prevent one death from colorectal cancer 
(Humphrey et al., 2013). Three trials comparing LDCT to annual clinical review or usual care 
reported lung cancer mortality rates that were not statistically different between randomized 
groups.   
All-cause mortality.  The NLST (Aberle et al., 2011) found a 6.7% reduction in all-
cause mortality between those in the LDCT group and those in the CXR group (95% CI, 1.2- 
13.6, p = 0.02).  The calculated NNS to prevent one death from any cause was 219 (95% CI, 
12 
112- 5,000).  In contrast, the three trials comparing LDCT to annual clinical review or usual care 
showed no difference in all-cause mortality rates (Infante et al., 2009; Saghir et al., 2012; 
Pastorino et al., 2012).   
Lung cancer-specific and all-cause mortality rates were only statistically significant in the 
NLST (Aberle et al., 2011) among the trials evaluated.  There are differences between these trials 
that may have influenced these findings.  The sample sizes among the four trials were quite 
different.  The NLST had a large sample size of 53, 454 persons enrolled, compared to 2472 
enrolled in DANTE, 4104 enrolled in DLCST, and 4099 enrolled in MILD (Aberle et al., 2011; 
Infante et al., 2015; Saghir et al., 2012, Pastorino et al., 2012).  There was likely not enough 
power in the DANTE, DLCST and MILD trials to find significant differences in lung cancer 
mortality and all-cause mortality rates.  The number of LDCT scans performed varied among the 
four trials, ranging from three annual LDCT scans in the NLST (Aberle et al., 2011) to five 
annual scans in both the DANTE and DLCST (Infante et al., 2015; Saghir et al., 2012).  Median 
time of follow-up also varied among the four trials.  The NLST (Aberle et al., 2011) followed 
patients for a median of 6.5 years.  This compares to the shorter durations in DANTE (Infante et 
al., 2015) where the median follow-up was 2.9 years for the intervention group and 2.6 years for 
the control group; DLCST (Saghir et al., 2012) median follow-up was 4.8 years; and MILD 
(Pastorino et al., 2012) median follow-up was 3.8 years for the LDCT group and 4.7 years for the 
control group.  This difference in follow-up may impact the power of the studies to show a 
benefit.  The number of average pack-year smoking history also varied among the trials.  Lung 
cancer incidence rates in the NLST and DANTE trial were higher than in the DLCST and MILD 
studies and is likely a reflection of more smoking exposure placing them at significantly higher 
risk of lung cancer.  The NLST (Aberle et al., 2011) reported the highest mean smoking history 
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of 56 pack-years; DANTE (Infante et al., 2015) reported mean smoking history of 47 pack-years; 
DLCST (Saghir et al., 2012) reported mean smoking history of 36 pack-years; and MILD 
(Pastorino et al., 2012) reported mean smoking histories of 38 and 39 pack-years. 
Stage at diagnosis.  All four studies in the review reported a positive impact of screening 
on early stage at diagnosis compared with CXR, annual clinical review, or usual care.  The 
NLST (Aberle et al., 2011) reported 51.8% (329 of 635) Stage 1A and 11.2% (71 of 635) Stage 
1B lung cancers in the LDCT group compared to 32.7% (90 of 275) Stage 1A and 14.9% (41 of 
275) Stage 1B lung cancers in the CXR group which was a significant difference.  DANTE 
(Infante et al., 2015) reported significantly more Stage 1 lung cancers in the LDCT group (53 of 
63, 84%) compared to the control group (12 of 35, 34%; p = 0.004).  DLCST (Saghir et al., 
2012) reported more early stage cancers (Stage 1 and 2) in the LDCT group compared to the 
control group (54 vs. 10, p < 0.001).  The MILD trial (Pastorino et al., 2012) reported 59% Stage 
1A lung cancers in the annual LDCT arm vs. 55% in the biennial arm vs. not reported in the 
control arm. 
The results from these four RCTs support LDCT screening as an effective method to 
detect cancers at an earlier stage of lung cancer diagnosis when conducted in similar patient 
populations and under similar clinical trial conditions.  The earlier stage at time of lung cancer 
diagnosis leads to more treatment options available to the patient and subsequent improvements 
in lung cancer mortality. 
Systematic reviews of lung cancer screening with LDCT since the publication of the 
NLST have assessed the risks versus benefits of LDCT (Bach et al., 2012; Gopal, Abdullah, 
Grady & Goodwin, 2010; Humphrey et al., 2013; Manser et al., 2013; Slator, Sullivan, Pappas & 
Humphrey, 2014; Usman et al., 2016).  The identified harms associated with LDCT lung cancer 
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screening include false-negative results, false-positive results, incidental findings, overdiagnosis, 
radiation exposure, and psychological distress (Moyer, 2014). The harms of false-negative 
results were not studied in the reviews.  However, the sensitivity of LDCT for detecting lung 
cancer ranged from 80-100%, implying a false-negative rate of 0-20% (Humphrey et al., 2013).  
False-positive results ranged from 9.2-51% of participants in baseline screens, with positive 
predictive values for abnormal studies ranging from 2.2-36%.  Most abnormal LDCT scans were 
resolved with further imaging. Positive examinations were lower in subsequent follow-up 
screens, with positive predictive values for abnormal studies ranging from 4-42%.  Positive 
predictive values for abnormal LDCT scans with recommendations for biopsy ranged from 50-
92% (Humphrey et al., 2013).   
There were no standardized approaches to reporting incidental findings among the 
studies. In LDCT studies, non-pulmonary findings of infections, other types of cancer and 
coronary artery calcification were commonly reported (Humphrey et al., 2013).  Overdiagnosis 
was not formally reported in the studies. However, four RCTs of LDCT which reported results in 
both the LDCT and no LDCT groups suggested overdiagnosis in only one trial showing an 
excess of 119 lung cancers among 26,722 participants after 6.5 years of follow-up (Humphrey et 
al., 2013).  Radiation associated with one LDCT scan ranged from 0.61 to 1.5 mSv in two RCTs 
and two cohort studies reported.  LDCT screening produces similar radiation exposure to 
mammography screening (United States Preventative Services Task Force, 2013).  Only one 
study reported cumulative radiation exposure associated with the LDCT screening program, 
which was estimated at 6 to 7 mSv (Humphrey et al., 2013).  Most studies reported no long-term 
differences in psychological distress among groups, but there was some evidence to suggest 
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increased short-term anxiety among those with positive or intermediate findings (Humphrey et 
al., 2013). 
In summary, evaluation of the current evidence affirms the need for continued 
development of standardized practices and guidance for not only the LDCT screening procedure, 
but also for follow-up testing to amplify accuracy, determine cost-effectiveness and reduce 
harms.  LDCT screening has proven to be an effective method to detect cancers at an earlier 
stage of lung cancer diagnosis leading to more available treatment options to the patient and 
subsequent improvements in lung cancer mortality.  However, patient, provider and system level 
barriers have been suggested as barriers to widespread adoption (Carter-Harris & Gould, 2017).   
Barriers to lung cancer screening.  Several studies have identified limited 
understanding of screening guidelines and LDCT effectiveness in lung cancer screening by PCPs 
as key barriers to appropriate screening referrals (Simmons et al., 2017; Lewis et al., 2015; Ersek 
et al., 2016; Klabunde et al., 2012).  These studies also indicate that a majority of PCPs would 
recommend LDCT screening to their high-risk patients if they had more information. Additional 
commonly identified barriers to recommendation of screening include perceptions about patient 
costs, potential harms from false positives, patient lack of awareness, risk of incidental findings 
requiring additional evaluation, risk of radiation exposure, patient stress and anxiety, and lack of 
insurance coverage.  Some of these studies also indicated that despite discussing the risks and 
benefits of lung cancer screening with their high-risk patients, many PCPs made no screening 
recommendations.  Additionally, physicians were more likely to order screening when they 
believed national expert organizations recommend lung cancer screening, when they perceive the 
screening test to be effective, and when high-risk patients ask about lung cancer screening. 
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The majority of PCPs in these studies identify early detection as the main benefit of 
LCDT screening (Simmons et al., 2017; Ersek et al., 2016); however, a low proportion believe 
that LDCT actually reduced lung cancer mortality (Ersek et al., 2016; Lewis et al., 2015).  
Primary care providers who believe that LDCT screening reduces mortality in the high-risk 
population are more likely to believe that screening and early detection has the potential to 
improve quality of life, improve overall outcomes, and motivate smoking cessation (Simmons et 
al., 2017).  In fact, Ersek and colleagues (2016) reported in the evaluation of the knowledge of, 
attitudes toward, and use of LDCT for lung cancer screening among family physicians that: 98% 
felt LDCT increased odds of detecting cancer at an earlier stage; 75% felt the benefits 
outweighed the harms; 76% discussed risks/benefits of LDCT in some capacity with their 
patients; yet >50% reported making one or no screening recommendations in the past year. 
Additionally, Lewis and colleagues (2015) assessed lung cancer screening practices and 
attitudes among PCPs in the era of new LDCT screening guidelines at an academic medical 
center.  The investigators found that few PCPs ordered lung cancer screening with approximately 
50% of the PCPs knowing three or more of the six guideline components for lung cancer 
screening (screen annually; begin screening at age 50 or 55; end screening at age 75 or 80; 20 or 
30 pack-years smoking history; current and former smokers; and not exposure to secondhand 
smoke only), and 24% knew none of the screening components.  This study showed that PCPs 
had a limited understanding of lung cancer screening guidelines and LDCT effectiveness with 
these knowledge gaps hindering the uptake of evidence-based lung cancer screening guidelines. 
In North Carolina, there is lack of information among health care providers (HCPs) 
regarding the process for coverage for North Carolina Medicaid enrollees meeting eligibility 
criteria for lung cancer screening (P. Rivera, personal communication, August 29, 2018).  Many 
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HCPs involved in the development and management of lung cancer screening clinics throughout 
the state continue to voice concerns over North Carolina Medicaid requests for coverage being 
denied for eligible high-risk patients (S. Skibo, personal communication, August 18, 2018).  
Most providers state confusion around the state’s administration of the CMS mandate to cover 
LDCT screening (L. Bowlby, personal communication, January 26, 2018).  Online resources 
regarding North Carolina Medicaid coverage for lung cancer screening are difficult to locate.  
Key North Carolina lung cancer screening thought leaders have little knowledge of the prior 
authorization requirement through the vendor, EviCore, with none reporting familiarity with this 
requirement or guidelines (P. Rivera, personal communication, August 29, 2018).  Currently, 
North Carolina Medicaid covers chest computed tomography (CT) without contrast under the 
current procedural terminology (CPT) code of CPT 71250 but not the usual LDCT lung 
screening code of G0297.  This creates a significant problem because this CPT code for chest CT 
does not require reporting findings in the consistent screening language of Lung-RADS (P. 
Rivera, personal communication, August 29, 2018).  Lung-RADS was created to standardize 
lung cancer screening CT reporting and management recommendations, reduce confusion in lung 
cancer screening CT interpretations, and facilitate outcome monitoring (American College of 
Radiology, 2018).  Given that CPT 71250 must be used to gain prior authorization for lung 
cancer screening in high risk Medicaid patients, inaccurate data collection on the number of 
LDCT screenings conducted in the North Carolina Medicaid population are likely occurring. 
 Lung cancer screening is the first cancer screening to require a shared decision making 
(SDM) component for reimbursement by CMS (Carter-Harris, Tan, Salloum, & Young-Wolff, 
2016).  Shared decision making is collaborative communication, which occurs between a patient 
and provider where the patient is the focus of care and the patient’s values regarding medical 
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decisions are considered (Delbanco & Gerteis, 2015).   The USPSTF outlines the content of the 
SDM conversation, which should occur prior to actual LDCT screening: advantages, limitations, 
known harms and potential harms (Moyer, 2014).    Billing code G0296 is utilized to document 
the SDM process. 
Despite PCPs recommending traditional cancer screening (such as mammography for 
breast cancer; pap smears for cervical cancer; and fecal occult blood, flexible sigmoidoscopy and 
colonoscopy for colorectal cancer), LDCT screening is not yet included in the PCP’s daily 
practice recommendations (Ersek et al., 2016).  Ersek and colleagues (2016) called for increased 
provider educational outreach to improve screening rates. By improving PCP knowledge of 
commonly identified barriers (lung cancer screening’s evidence base, guidelines, potential 
harms, and reimbursement) and reinforcing the confirmed benefits, lung cancer screening can be 
enacted to improved lung cancer mortality.   
Theoretical Framework 
 
The importance of using science-based concepts to evaluate and enhance health care 
delivery and improve patient outcomes is critical to evidence-based practice.  Equipping the 
clinician to appropriately discuss risks and benefits and refer high risk patients for lung cancer 
screening and to discern how to best disseminate and implement this knowledge should be 
informed by evidence rather than opinion or belief. 
Rogers' Diffusion of Innovations Theory (1962) has been used to examine research 
utilization in many disciplines, and may offer insights to the diffusion of ideas and practices 
related to guideline recommended lung cancer screening among clinicians.  Rogers’ theory 
suggests that when the individual perceives information as new knowledge or evidence 
(“innovation”), the reaction to the innovation determines how that individual will begin to adopt 
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the new idea.  Utilizing Roger’s theory as a guiding framework for targeted educational efforts 
and implementation of a lung cancer risk screening tool can improve evidence-based practice 
and patient outcomes.  
Rogers’ theory is a group of ideas that provide a description and explanation of the 
phenomenon by which new ideas, products, or behaviors spread over time throughout a society 
or organization (Nilsen, 2015). The result of this diffusion is the adoption of the idea, product or 
behavior as part of the social system. The key to adoption is the perception of this idea, product 
or behavior as new or innovative. Interpersonal influence of opinion leaders or change agents, 
and the adoption decisions of targeted individuals are the keys to spreading the innovation 
(Greenhalgh, Robert, Macfarlane, Bate & Kyriakidou, 2004).   
Rogers (1962) described five adopter classifications on the basis of innovativeness 
(innovators, early adopters, early majority, late majority and laggards). The rate of adoption is 
the relative speed with which the members of the social system adopt an innovation and early 
adopters have different characteristics than those who are slower to adopt.  The new idea or 
innovation is communicated through successive diffusion stages over a period of time to 
members of the social system (Rogers, 2002). This diffusion may be passive or active.  Rogers 
also describes five process factors that influence the rate of adoption: knowledge, persuasion, 
decision, implementation and confirmation.  These major components of Rogers’ theory will 
inform the process of diffusion and dissemination of lung cancer screening education and 
screening tool within the practice site with the aim to increase referrals for LDCT in high-risk 
individuals. 
When Rogers’ theory is applied to evidence-based lung cancer screening 
recommendations in clinical practice, the goal is to guide the spread of research to address the 
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identified knowledge or behavior gap in targeted clinicians’ practices (Greenhalgh, Robert, 
Macfarlane, Bate & Kyriakidou, 2005). The PCP is well positioned to assist the patient with 
decision-making for preventative screening interventions as they represent the initial point of 
care coordination of preventative care in the United States.  Studies have identified the PCP’s 
lack of knowledge of lung cancer screening (Simmons et al., 2017), lack of knowledge of 
guidelines (Lewis et al., 2015), and lack of knowledge of payment and reimbursement (Ersek et 
al., 2016) as key barriers to appropriate screening.  Reinforcing the confirmed benefits of and 
improving PCP knowledge of barriers to screening can lead to improved lung cancer mortality 
through earlier detection. The diffusion of innovation theory may prove a beneficial framework 
to efficiently spread this evidence-based research knowledge into clinical practice. 
According to Rogers’ theory, when promoting an innovation such as lung cancer 
screening, it is important to understand the characteristics of the target population that will assist 
or hinder the adoption into practice.  Rogers contends there are five established adopter 
categories with different strategies useful in appealing to the different adopter categories.   
Knowing that most clinicians in the implementation site will fall into the middle categories of 
early adopters, early majority, and late majority, providing strategies (such as success stories and 
evidence of success) to appeal to these providers will be important to adoption of the lung cancer 
screening initiative.   
Adoption of an innovation by an individual is a process rather than a single event and is 
often dependent upon other decisions within an organization (Rogers, 2003).  The rate of 
innovation diffusion is related to the five attributes of the innovation: (1) the adopter's perception 
of the relative advantage of the innovation; (2) the compatibility of the innovation with existing 
structures; (3) the perceived degree of difficulty involved in adopting the innovation; (4) the 
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testability of the innovation, in the absence of significant resources; and (5) the visibility of 
outcomes resulting from adoption of the innovation (Rogers, 1995).    
The five-step innovation-decision process of individual stages by which a person adopts 
an innovation includes: knowledge, persuasion, decision, implementation, and confirmation. If 
the innovation has greater relative advantage to the one it is to replace, and if the innovation is 
consistent with existing beliefs, values, past history and practice needs, the adoption will occur 
more quickly.  If the innovation is easy to understand and use and is of low complexity, it will be 
adopted sooner.  If the innovation can be piloted to see its advantages, and it is observable and 
seen by others in the social system considering adoption, it will likely diffuse more rapidly.  
This project will address the identified key barriers to practice implementation, which 
will be targeted toward the informational needs at the practice site (such as the closest certified 
LDCT screening location, requirements for referral, reimbursement, and processes for both SDM 
conversations and follow up of abnormal findings).  The use of a simple lung cancer risk 
screening tool embedded into the practice electronic health record (EHR) which is relatively 
quick and easy for the PCP to identify the at-risk patient is of great importance.  A pilot of the 
screening tool will be conducted with intended users prior to formal launch of the tool to assess 
gaps in future implementation.   
There are three identified types of innovations knowledge:  awareness knowledge, how-to 
knowledge, and principles knowledge.  Studies have shown that the majority of potential 
adopters do not base their decision on scientific studies, but prefer to receive subjective 
information from a peer within their social system.  When considering implementation of the 
lung cancer risk screening tool, using an early adopter influencer from within the social system 
to provide information and support will be key in communicating the benefits of screening.   
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Limitations of Rogers’ theory include the fact that although the S-shaped curve and the 
adopter categories were originally developed as a descriptor model, it cannot explain how or why 
people adopt innovations at different rates or if adoption will be successful (Greenhalgh et al., 
2005).  Rogers’ theory does not promote an active participation in adoption of the innovation, 
which newer research has found to be more effective in individual behavior change.  One review 
found that more active interventions, such as HCP reminders and educational outreach, were 
more effective in changing provider behavior than passive interventions (Ellis et al., 2005).  
Rogers’ theory serves as a necessary schema for translating evidence-based lung cancer 
screening guidelines into clinical practice to effectively and efficiently improve health outcomes 
in patients at high risk of lung cancer.  Lung cancer screening initiatives must be perceived as not 
only advantageous with low implementation complexity, but also readily adaptable with clear 
advantages in order to promote its adoption into clinical practice.  Without the guiding 
framework of Roger’s diffusion of innovation theory, there would be a lack of understanding of 
both the engagement of potential adopters of lung cancer screening at the proposed clinical site 
and the innovation-decision process and possible obstacles to adoption.  A lack of understanding 
of the patterns of adoption by individuals could potentially lead to unsuccessful implementation 
of the lung screening education and tool due to the lack of utilization of key opinion leaders to 
influence the behavior of potential adopters. 
Rogers’ Diffusion of Innovations Theory provides understanding of the complexities 
involved in the process of adopting new ideas and practices, such as the evidence-based care 
practice of lung cancer screening in high-risk adult populations.  Rogers’ theory can serve to not 
only identify, but also direct efforts at individual and organizational levels to facilitate lung 
cancer screening adoption. Several studies have demonstrated improvements in process measures 
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such as knowledge but failed to demonstrate changes in individual provider behavior (Raz et al., 
2018).   This practice change project aims to increase lung cancer screening rates by translating 
this new knowledge into behavior change. 
LDCT screening guidelines have not been widely implemented into national evidence-
based clinical practice (Pham et al., 2018).  Many patient, provider and system level barriers 
have been suggested as reasons for low screening rates (Carter-Harris & Gould, 2017).  Despite 
North Carolina Medicaid enrollees reporting current smoking rates of 43.3%, placing these 
enrollees at high risk for lung cancer while also being at high risk for healthcare disparities due 
to their socioeconomic status (State Center for Health Statistics, North Carolina Department of 
Public Health, 2016), current lung cancer screening rates in this population are not known.  Can 
implementation of a lung cancer screening assessment tool into a rural community practice EHR 
improve PCP’s identification of North Carolina Medicaid enrollees at high risk for lung cancer 
and increase appropriate referrals for LDCT screening?   
Study Outcomes 
 
The primary outcome of this study was to evaluate change in primary care provider 
behaviors in LDCT screening referrals (number who were eligible and referred for LDCT 
screening, number who were eligible and not screened, and number who were eligible but 
refused LDCT referral) following provider education and implementation of a lung cancer risk 
assessment tool. Secondary outcomes included collection of descriptive data regarding the total 
Medicaid practice sample cohort in addition to the patient sample for LDCT referral cohort 
before and after implementation of the project.    
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CHAPTER 2: METHODS 
 
The goal of this DNP quality improvement project was to improve lung cancer screening 
in eligible North Carolina Medicaid recipients. The process to improve screening included 
incorporating a lung cancer risk assessment tool into the practice EHR to assist the PCP to 
appropriately identify eligible patients for LDCT screening to increase appropriate LDCT 
screening referrals.  
Setting and Participants 
 
Site implementation was conducted at a busy family practice in rural Vance County, 
North Carolina.  The office has four physicians and 11 physician assistants caring for patients.  
The investigator worked closely with a Physician Assistant (PA), who serves as lead for quality 
practice improvement projects and liaison between the investigator and key personnel at the 
practice site.  The practice site has an electronic medical record (AllScripts), which is well-
incorporated into daily clinic practice.   
According to North Carolina County Rankings, Vance County ranks 14th in lung cancer 
mortality rate of 59.8 per 100,000 (2011-2015) compared to North Carolina mortality rate of 
49.0 per 100,000 (North Carolina Cancer Prevention and Control Branch/N.C. Comprehensive 
Cancer Control Program, 2017). Vance County also ranks 18th in distant stage at diagnosis 
(2010-2014), and 1st in current smoking rates (2012) (North Carolina Cancer Prevention and 
Control Branch/N.C. Comprehensive Cancer Control Program, 2017).  In fact, Vance County 
reports percentage of current smokers at 29%, which outpaces North Carolina’s overall 
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percentage of 21% (North Carolina Cancer Prevention and Control Branch/N.C. Comprehensive 
Cancer Control Program, 2017).  Additionally, Vance County is among the six North Carolina 
counties with the highest percent of people enrolled in NC Medicaid as of January 2017, ranging 
between 32-40% (Toledo, 2017).  North Carolina Medicaid smoking rates are higher than for 
other North Carolinians placing these enrollees at high risk for lung cancer.  The State Center for 
Health Statistics, North Carolina Department of Public Health (2016) conducted a study, which 
showed that 43.3% of non-institutionalized adults aged 18-64 years enrolled in North Carolina 
Medicaid reported current smoking. 
Design and Data Collection 
 
This practice change project was designed to aid the adoption of evidence supported lung 
cancer screening into primary care clinical practice by incorporating a lung cancer risk 
assessment tool into the existing EHR to facilitate providers screening and referral. Data was 
gathered for three months before and after implementation of the lung cancer risk assessment 
tool in order to evaluate the impact on provider lung cancer screening behavior.  
As lung cancer screening is complex, the review of the literature has emphasized that 
education of the provider is important in lung cancer screening and was provided prior to 
implementation of the screening tool (Simmons et al., 2017; Lewis et al., 2015; Ersek et al., 
2016; Klabunde et al., 2012).  A 15-minute education session with providers was delivered in 
conjunction with a PowerPoint presentation (Appendix C) addressing national, state and county 
specific lung cancer statistics, LDCT screening benefits and risk, USPSTF guideline 
recommendations, review of the Agency for Healthcare Research and Quality (AHRQ) decision 
aid tool (“Is Lung Cancer Screening Right for Me:  A Decision Making Tool for You and Your 
Clinician” and “Lung Cancer Screening:  A Clinician’s Checklist”), review of the SDM 
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conversation and documentation, overview of North Carolina Medicaid coverage requirements, 
coding and prior authorization process, and overview of the resource/ referral guide.  For those 
providers unable to attend the education session, the PowerPoint presentation was emailed to 
them for review.  The PowerPoint was also emailed out to all practice HCPs for their reference.  
The site quality improvement lead informed office and nursing staff of the procedure of 
documenting information for the eligible patients’ visits.  No letters or phone calls were made to 
proactively recruit patients to for LDCT screening assessment.  Patients were evaluated as they 
presented for a scheduled appointment to more closely represent a PCP office without staff 
dedicated to a lung cancer screening program. 
Upon registration at the clinic on the day seen, patients who were North Carolina 
Medicaid enrollees (single coverage or dual eligible), age 55-80 years, and had a documented 
smoking history in the EHR were identified as eligible for participation (Appendix D) and were 
given a “Is Lung Cancer Screening Right for Me:  A Decision Making Tool for You and Your 
Health Care Professional” (Appendix E) form from a tear-pad kept at the check-in desk to 
complete while waiting in the lobby for their appointment.  If the front office personnel missed 
handing the form to the patient at check in, the medical assistant/ nursing staff were to provide 
this tear-pad form to the patient for completion while waiting in the room for the PCP.  The form 
was to then be handed to the PCP by the patient and the information would be reviewed together 
to calculate the pack year history and assess the patient’s risk for lung cancer, undergo a SDM 
conversation, provide smoking cessation counseling if needed, and refer for LDCT screening if 
appropriate.   
Demographic and outcomes data was extracted from the clinic EHR system.  Data on zip 
code to determine rural versus urban living address, race/ ethnicity, gender and age were 
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collected to describe the population. No protected health information (PHI) was collected.    
Outcomes data included use of codes G0297 (LDCT screening) and CPT 71250 (diagnostic CT).  
The actual chart was reviewed if the patient was eligible for LDCT screening but referral was not 
ordered or if the patient refused LDCT screening referral. Data were entered into an excel 
spreadsheet.  The clinic’s EHR could not be altered to allow for discreet fields for documentation 
of the seven questions to assess the risk of lung cancer for North Carolina Medicaid enrollees. 
Therefore, the decision was made to embed a .pdf of the seven questions into the EHR 
(Appendix G).  Upon a North Carolina Medicaid enrollee with smoking history presenting to the 
clinic, documentation of patient aged 55-80 years triggered subsequent screening questions 
consistent with NC Medicaid lung cancer screening criteria (EviCore, 2018).  These questions in 
the .pdf tool included: 
1. Is the patient between 55-80 years of age?  Yes/No 
2. Calculate pack-years smoking history with formula: number of years smoked x average 
number of packs smoked per day = pack years ___ Number 
3. Does the patient have at least a 30 pack-year history of cigarette smoking? Yes/ No 
4. Does the patient currently smoke or quit less than 15 years ago? Yes/ No 
5. Is the patient asymptomatic of underlying lung cancer symptoms? Yes/No 
6. Is the patient willing to undergo curative lung surgery? Yes/ No 
7. Has the patient receive a low-dose CT lung screening in less than 12 months? Yes/ No 
It is important to mention that none of these questions, including smoking pack year 
history, were mandatory (“hard stops”) for completion by the clinician or clinic staff.  Due to the 
risk of provider “pop-up fatigue,” electronic pop-up reminders were not utilized in this project.  
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If the patient met all North Carolina Medicaid criteria for high risk of lung cancer, the 
provider then entered into a SDM conversation with the patient reviewing the benefits and risks 
of LDCT lung cancer screening followed by smoking cessation and smoking abstinence 
counseling, if needed.  This SDM visit included review of the decision aid titled “Is Lung Cancer 
Screening Right for Me?” developed and published by AHRQ.  The provider then documented 
the SDM discussion and decision.  If the patient met all criteria and chose to receive LDCT 
referral for screening, a written order for the lung cancer screening visit with required 
information was generated from the EHR.  As currently is the practice, the Department of 
Radiology continued to perform prior authorization prior to the LDCT scan.  If the patient 
declined LDCT screening, the rationale for that decision was to be documented in the EHR.  If 
the patient was unsure about referral for LDCT screening or requests more time, the patient was 
to be scheduled for a follow-up clinic visit to discuss the screening decision.  Documentation of a 
smoking cessation and abstinence counseling session continued to be required for all patients 
who were currently smoking. 
Baseline chart review of three months prior to implementation (October 19, 2018 through 
January 18, 2019) determined the number of North Carolina Medicaid enrollees aged 55-80 
years of age who were current or former smokers and eligible for LDCT screening assessment.   
Following the first four weeks of implementation, there was a low uptake of utilizing the 
AHRQ decision aid tool by the registration or medical assistant/ nursing staff.  The decision was 
made to move these tear-pad sheets into each of the 17 patient examination rooms and to provide 
a laminated copy for each room for the clinician to use with the decision aid.  The one-page .pdf 
tool was also emailed to all practice PCPs as a reminder (Appendix G).  This resource included 
current national, state and county lung cancer statistics; the seven question risk assessment tool; 
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suggested documentation requirements; and reimbursement coding for quick reference. 
Reminders to the HCP to document required components of SDM, use of a decision aid, and 
smoking cessation and abstinence counseling were included in the resource. 
At the conclusion of the three-month implementation pilot (January 19, 2019 through 
April 19, 2019), change in provider lung cancer screening behaviors were measured compared to 
baseline (number who were eligible and referred for LDCT screening, number who were eligible 
and not screened, and number of eligible patients refusing LDCT referral).  Due to the short 
duration of this pilot project we were not able to evaluate those who actually completed the 
LDCT once referred, nor the number of lung cancers detected upon LDCT referral.  
The project was submitted to the University of North Carolina at Chapel Hill Institutional 
Review Board (IRB) for review and approval.  The University of North Carolina at Chapel Hill 
IRB determined the submission did not constitute human subjects research as defined under 
federal regulations and did not require IRB approval.   
Statistical Analysis 
 
Descriptive statistics were used to analyze data regarding pre- and post-implementation 
patient demographics and variables related to LDCT screening.  These tests included mean, 
median, minimum, maximum, frequencies and percentages.  IBM SPSS Statistic software 
program was used to calculate the descriptive statistics for the study patients.  To determine if 
the implementation of the risk assessment tool led to improved rates of LDCT referrals for 
Medicaid enrollees, the number who were eligible and referred for LDCT screening, number 
who were eligible and not screened, and number who were eligible but declined LDCT referral 
were compared before and after implementation using two proportion z-tests.  The two 
proportion z-test was utilized to determine whether the proportion of those eligible and referred 
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for screening, eligible and not screened, and eligible but declined referral are the same in the two 
groups.  The sample size was greater than 30 with known mean and standard deviation.  The z-
test was also chosen because the number of eligible patients was almost equal with normal 




CHAPTER 3: RESULTS 
 
Total Practice Medicaid Patients- Eligible, Did Not Participate: Demographics, Smoking 
History, Symptomatology and Smoking Cessation Counseling 
To understand the population of Medicaid patients seen in this rural primary care 
practice, demographics related to age, gender, race, ethnicity, insurance and zip code were 
collected (Appendix H, Table 1).  Additional information on pack-year smoking history, 
symptomatology and smoking cessation counseling was collected.  Of the 184 Medicaid patients 
evaluated in the clinic during the study period, 150 of the total Medicaid practice sample were 
eligible but did not participate (were Medicaid enrollees- either single coverage or dual eligible; 
age 55-80 years; and positive smoking history).   
Patient Sample: Demographics, Smoking History, Symptomatology Smoking Cessation 
Counseling 
Thirty-four patients met eligibility criteria for lung cancer screening (were Medicaid 
enrollees; age 55-80; documented pack-years smoking history; and were asymptomatic) 
(Appendix I, Figure 2).  The pre- and post-implementation cohorts of the patient sample (N=34) 
had similar demographics without any statistically significant differences found between groups 
(Appendix J, Table 2).  There were also no significant differences between the pre- and post-
implementation cohorts of patients related to pack-years smoking history and symptomatology 
(Appendix K, Table 3).  Additionally, there were no significant differences in smoking cessation 
counseling, if needed, after implementation compared to before (Appendix L, Table 4). 
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Comparison of Total Medicaid Patient Sample and Eligible Patient Sample 
The total practice Medicaid population (N=150) differed significantly from the eligible 
patients (N=34) in several areas (Appendix H, Table 1). 
Age.  The patients in the total Medicaid practice cohort were statistically significantly 
younger than the eligible patient cohort.  The total Medicaid practice cohort had a mean (SD) 
patient age of 61.9 (4.87) years while the patient sample (N=34) were older with a mean (SD) 
age of 66.5 (5.25) years (p=0.00004). 
Gender.  There were no significant differences between the proportion of females 
(p=0.59) and males (p=0.59) in each cohort. The total Medicaid practice cohort had a higher 
proportion of females (n=85, 56.7%) compared to males (n=65, 43.3%).  Similarly, the 
proportion of females (n=21, 61.8%) in the eligible patient group was higher than males (n=13, 
38.2%). 
Race.  The total Medicaid population had a statistically significantly higher proportion of 
Black/ African Americans (n=81, 54.0%) compared to the eligible patient group of Black/ 
African Americans (n=7, 20.6%, p=0.00008).  The total Medicaid practice population also had a 
statistically significantly lower proportion of White/ Caucasians (n=63, 42%) than the patient 
sample (n=27, 79.4%, p=0.00008). 
Ethnicity.  There were no significant differences in ethnicity between the total Medicaid 
practice population and the eligible patients.  There were low proportions of Hispanic/ Latinos 
(n=5, 3.3%) in the total Medicaid practice population while there were none in the eligible 
patient group (p=0.28).  There was a high proportion of the total Medicaid practice population 
identified as Not Hispanic/ Not Latino (n=142, 94.6%) as well as in the eligible patient group 
(n=34, 100%, p=0.17). 
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Insurance.  The total Medicaid practice population had a statistically significantly higher 
proportion of patients with North Carolina Medicaid only (n=58, 38.7%) compared to the 
eligible patient group (n=5, 14.7%, p=0.01).  The total Medicaid practice population had a 
statistically significantly lower proportion of patients with dual eligibility with North Carolina 
Medicaid and Medicare (n=92, 61.3%) compared to the eligible patients (n=29, 85.3%, p=0.01).  
Zip code.  There were no significant differences between zip codes of the two cohorts.  
The total Medicaid practice population had a similar proportion of patients from within the 
immediate Vance County area zip codes of 27536 and 27537 (n=108, 72%) compared to all other 
zip codes outside of Vance County.  The proportion of eligible patients from within the 
immediate Vance County area zip codes of 27536 and 27537 was 67.6% (n=23) compared to zip 
codes outside of Vance County. 
Pack-year smoking history and symptomatology.  There was a high proportion of 
patients in the total Medicaid practice population who had no pack-year history documented 
(n=118, 78.7%).  A significantly higher proportion of the eligible patients had a documented >30 
pack-year smoking history (n=23, 67.6%) compared to the total Medicaid practice population 
(n=28, 18.7%, p=0.00001).  A significantly higher proportion of the eligible patients had a 
documented <30 pack-year smoking history (n=11, 32.6%) compared to the total Medicaid 
population (n=4, 2.7%, p=0.00001).    
Of the total Medicaid practice population with a documented pack-year history (n=32), 
all were symptomatic (100%) and were determined ineligible for LDCT lung cancer screening.  
None of the 34 patients eligible for LDCT lung cancer screening were symptomatic. 
Smoking cessation counseling.  There were no significant differences between the 
proportion of patients receiving smoking cessation and abstinence counseling, if needed, 
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between the cohorts.  Overall, a slightly higher proportion of the eligible patients received 
smoking cessation counseling, if needed, (n=17, 50%) compared to the total Medicaid practice 
population (n=60, 40%, p=0.285). 
Primary Outcome Measure: Referred for LDCT Screening 
To measure improvement in LDCT screening referrals of the eligible patients (N=34), 
referral was determined as either “yes” or “no”.  There was not a statistically significant 
improvement in referrals following implementation (p = 0.23).  There were more patients 
referred for LDCT screening during the post-implementation period (n=3, 19%) compared to the 
pre-implementation period (n=1, 6%) but this did not reach statistical significance (Appendix M, 
Table 5). 
Secondary Outcome Measure: Not Referred for LDCT Screening 
Patients who met all criteria for LDCT screening referral yet were not referred were 
determined as either “yes” or “no”.  There was no statistically significant change in the 
percentage of patients who met all eligibility criteria for LDCT screening but were not referred 
between and pre-implementation (n=11, 61%) and post-implementation (n=8, 50%) groups 
(p=0.51) (Appendix M, Table 5).   
Secondary Outcome Measure: Referred and Declined LDCT Screening 
There were no patients in either of the pre- or post-implementation cohorts who were 





CHAPTER 4: DISCUSSION 
 
The goal of this DNP quality improvement project was to improve lung cancer screening 
in eligible Medicaid recipients in a rural primary care practice. The process to improve screening 
included incorporating a lung cancer risk assessment tool into the practice EHR to assist the PCP 
to appropriately identify eligible patients for LDCT screening and to increase appropriate LDCT 
screening referrals. Thirty-four patients met the USPSTF lung cancer screening eligibility criteria 
(ages 55-80, documented pack-year smoking history and asymptomatic) from the Medicaid 
practice population (N=184) seen during the study period.  Data was gathered for three months 
before and after implementation of the lung cancer risk assessment tool in order to evaluate the 
impact on provider lung cancer screening behavior. Our project found no significant 
improvement in the primary outcome of LDCT screening referrals.  Post-implementation 
screening rates in this study increased to 19%; however, this was not statistically significant.   
National LDCT lung cancer screening rates are low at 1.9% in the general population 
(Pham et al., 2018).  Pre-implementation screening rates in this study were higher at 5.6%, and 
were consistent with other research findings of LDCT screening rates of 5.8% in a high-risk 
smoker population in California in the National Health Interview Surveys (Li, Chung, Wei & 
Luft, 2018).  There is currently no data published on the estimated or actual numbers of lung 
cancer screenings in the North Carolina general population or in the North Carolina Medicaid 
population for comparison.   
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A high proportion of patients in our total Medicaid practice population had no pack-year 
smoking history documented (n=118, 78.7%).  Recommending LDCT screening in a targeted, 
high-risk population is designed to decrease the burden of screening (including false-positive 
follow-up and screening anxiety) (Goulart & Ramsey, 2013). Incomplete documentation of 
smoking history to include accurate pack-year history can negatively impact the numbers of 
patients who actually meet USPSTF lung cancer screening criteria.  Smoking history 
documentation remains an area for improvement at this practice site for continued improvement 
in LDCT screening referral rates. 
Determining screening eligibility can remain confusing for the PCP even when the pack-
year smoking history is known.  Research has shown that selection of patients for LDCT 
screening using an individualized risk assessment tool is superior (greater sensitivity and 
specificity) to the current eligibility criteria based on patient age and pack-year smoking history 
alone (O’Dowd & Baldwin, 2017).  In this project there was a non-statistically significant 
improvement in the proportion of patients who met all criteria for LDCT referral in the post-
implementation cohort (n=8, 50%) but were not referred compared to the pre-implementation 
cohort (n=11, 61.1%).  The three patients who were referred for LDCT screening during the 
post-implementation period were also seen in the pre-implementation period but were not 
referred at that time despite knowing the age, pack-year smoking history and symptomatology.  
Review of the EHR revealed no documented reason why they were not initially considered or 
evaluated for LDCT referral as they did meet USPSTF eligibility criteria at that time.  It is 
plausible that the education efforts in this project, combined with the lung cancer risk assessment 
screening tool, were effective in prompting the PCP to evaluate these patients on their 
subsequent visits for eligibility for LDCT screening referral. Utilizing a LDCT screening tool 
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may be challenging during a primary care visit but is an important aspect of expanding clinician 
knowledge and changing clinician behavior (Li et al., 2018). 
Importantly, all patients referred for LDCT during both the pre-implementation period 
(n=1) and the post-implementation period (n=3) had documentation of all required elements for 
payor coverage.  Additionally, all patients who were referred for LDCT during both the pre- and 
post- implementation periods (n=4) had documentation of smoking cessation and abstinence 
counseling.  
Recent debate has questioned if the current USPSTF lung cancer screening guidelines are 
too stringent to apply to African American adult smokers, suggesting that the guidelines may be 
too conservative for this specific population citing racial differences in smoking patterns 
(Aldrich et al., 2019).  Our study found African Americans represented only 21% (n=7) of 
eligible patients using current USPSTF lung cancer screening eligibility criteria. Suggestions for 
modification of the eligibility criteria for this population include decreasing the current 30 pack-
year eligibility to 20 pack-years, as well as decreasing the minimum age to begin consideration 
for LDCT lung cancer screening from the current 55 years to 50 years (Aldrich et al., 2019).  Our 
study quantified pack-year history as only >30 or <30 pack-years.  However, proactively looking 
at more descriptive pack-year smoking quantities could help to inform future screening criteria 
for specific populations.  Although decreasing the USPSTF recommendations in the adult 
African American smoker population may increase the percentage eligible for screening, these 
suggestions are not recommended in current guidelines or in clinical practice as it would likely 
result in failure of payment by CMS and private insurances. 
Smoking cessation and abstinence counseling remains a cornerstone of a successful 
LDCT lung cancer screening program.  All eligible patients (N=34) were current smokers with 
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pack-year history documented.  Despite this information, there was no change in the proportion 
of patients with documented smoking cessation counseling during the pre- and post-
implementation periods.  There continues to be a need for PCP and staff education and 
clarification around the issue of smoking cessation and abstinence counseling as well as 




CHAPTER 5: LIMITATIONS AND PRACTICE IMPLICATIONS  
 
Limitations of this study include the small patient sample (N=34), which may contribute 
to the lack of statistically significant findings and limits the generalizability to a larger 
population.   
Additional limitations include the lack of significant process changes during the project.  
The low uptake of utilizing the AHRQ decision aid tool by the registration or medical assistant/ 
nursing staff was identified following the first month of implementation.  Only a small change 
was made in the ownership of distribution of the decision aid to the PCP.  During a practice 
change project of this type, one would expect implementing changing the intervention utilizing 
PDSA cycles to improve smoking history documentation and uptake of the screening tool. The 
Plan-Do-Study-Act (PDSA) cycle is a commonly used improvement process in health care 
settings that uses small tests of change to optimize a process (Coury et al., 2017).  However, as a 
DNP student with limited access to the clinic, staffing and data at the study site, these results 
may have been different than if employed full-time at the site with daily presence to enact 
changes to improve smoking history documentation and uptake of the screening tool. 
Due to the short duration of the pilot project, the outcomes of the LDCTs ordered were 
not evaluated, which would be monitored in a real life clinical setting.   
Recommendations for future work include continuing to review and improve upon the 
process of gathering accurate USPSTF lung cancer screening patient eligibility criteria of pack-
years smoking history and documenting this in the EHR.  This work will allow for automation of 
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appropriate patient identification for screening from the EHR database.  Specific questions to be 
investigated in future analyses include:   
• How does the documentation of pack-year smoking history improve LDCT referral rates 
in a high-risk North Carolina Medicaid population? Comparisons from this site could 
then be compared to other primary care practice sites within North Carolina.  
• What is the impact of this project on the LDCT screening referral rates in the non-
Medicaid patients within the practice?  This information could inform about PCP 




CHAPTER 6: CONCLUSIONS 
 
LDCT screening guidelines have not been widely implemented into national evidence-
based clinical practice as evidenced by a low national lung cancer screening rates.  The PCP 
most often represents the initial point of coordination of preventative care and is an important 
link between the high-risk lung cancer patient and the LDCT screening center.  The PCP is well 
positioned to assist the patient with decision-making for lung cancer screening interventions. 
However, the PCP needs system changes to facilitate this process. While this single site quality 
improvement project did not show improvement in LDCT screening referral rates, it does 
provide data on current LDCT referral rates in a high-risk North Carolina Medicaid population 
which is currently not in the published health care literature. 
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APPENDIX E: AHQR “IS LUNG CANCER SCREENING RIGHT FOR ME.  A 
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Meets Criteria for LDCT Screening (Screened with 
LDCT, Meets criteria but NOT screened, Ordered 
by patient did not go; HCP offered LDCT but no 
documentation of pack years; Unable to verify if 
qualified- unknown pack years; Does NOT meet 
criteria- symptomatic; Does NOT meet cireria, <30 
pack years; Does not meet criteria- Other; Already 
had LDCT screening ordered)
ID- Identification number CXR- Chest X-ray
LCS- Lung cancer screening CT- Chest tomography
LDCT- Low-dose chest tomography HCP- Healthcare provider
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•Does the patient have BOTH NC Medicaid and are between the ages of 55-80 ? Yes or No
Calculate 
Pack Years
•Calculate pack-years smoking with formula: # of years smoked X average number of packs smoked per 
day = pack years ___ (Number)
If Yes, 
Continue
•Does the patient have at least a 30 Pack-Year history of cigarette smoking? Yes or No
If Yes, 
Continue
•Does the patient Currently smoke or they quit less than 15 years ago? Yes or No
If Yes, 
Continue
•Is the patient Asymptomatic of underlying lung cancer symptoms? Yes or No
If Yes, 
Continue
•Is the patient willing to undergo curative lung surgery? Yes or No
If No, 
•Has the patient received a low-dose CT lung screening in less than 12 months? Yes or No
RISK ASSESSMENT FOR LCDT LUNG CANCER SCREENING
§Written order for LDCT for lung cancer screening with required information documented (EMR)- Physician, 
NP, PA or CNS
§Beneficiary date of birth
§Actual pack-year smoking history (number)
§Current smoking status, and for former smokers, the number of years since quitting
§Statement that the beneficiary is asymptomatic
§National Provider Identifier (NPI) of the ordering practitioner
§Department of Radiology continues to obtain prior authorization for LDCT (EviCore prior authorization 
requirement)
Patient AGREES to 
have LDCT lung 
cancer screening:  
G0297
(not diagnostic CPT 
71250 )
§Schedule follow-up visit to discuss
Patient UNSURE of 
LDCT lung cancer 
screening:
§Document rationale in EMR
Patient DECLINES
LDCT lung cancer 
screening:
If patient meets all criteria above:
§ Document required lung cancer screening shared-decision-making (SDM) conversation (risks vs. benefits)- G0296
§ Document use of decision aid:  “Is lung cancer screening right for me?” Agency for Healthcare Research and Quality (AHRQ)
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APPENDIX I: CONSORT DIAGRAM 
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Figure 2.  Consort Diagram 
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